ARK Investment Management LLC Has $203.65 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

ARK Investment Management LLC increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 200.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,654,287 shares of the company’s stock after purchasing an additional 13,777,689 shares during the quarter. Recursion Pharmaceuticals makes up approximately 1.2% of ARK Investment Management LLC’s holdings, making the stock its 24th biggest holding. ARK Investment Management LLC owned approximately 9.53% of Recursion Pharmaceuticals worth $203,651,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Recursion Pharmaceuticals by 37.7% during the 3rd quarter. Vanguard Group Inc. now owns 15,506,834 shares of the company’s stock worth $118,627,000 after purchasing an additional 4,247,002 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Recursion Pharmaceuticals by 9.3% in the 2nd quarter. BlackRock Inc. now owns 11,619,427 shares of the company’s stock valued at $86,797,000 after purchasing an additional 987,570 shares during the last quarter. FMR LLC raised its position in shares of Recursion Pharmaceuticals by 134.4% in the 3rd quarter. FMR LLC now owns 10,689,532 shares of the company’s stock valued at $81,775,000 after acquiring an additional 6,129,935 shares during the period. Laurion Capital Management LP raised its position in shares of Recursion Pharmaceuticals by 5.2% in the 4th quarter. Laurion Capital Management LP now owns 4,825,735 shares of the company’s stock valued at $37,206,000 after acquiring an additional 238,461 shares during the period. Finally, State Street Corp raised its position in shares of Recursion Pharmaceuticals by 114.3% in the 3rd quarter. State Street Corp now owns 4,555,759 shares of the company’s stock valued at $48,473,000 after acquiring an additional 2,430,027 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Down 1.5 %

NASDAQ RXRX opened at $10.17 on Thursday. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.54 and a 12-month high of $16.75. The firm’s 50 day moving average is $11.16 and its 200-day moving average is $9.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.06. The company had revenue of $10.89 million for the quarter, compared to the consensus estimate of $12.37 million. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Christopher Gibson sold 48,272 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $9.22, for a total transaction of $445,067.84. Following the transaction, the chief executive officer now directly owns 774,703 shares in the company, valued at $7,142,761.66. The sale was disclosed in a filing with the SEC, which is available through this link. In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 48,272 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $9.22, for a total value of $445,067.84. Following the transaction, the chief executive officer now directly owns 774,703 shares in the company, valued at $7,142,761.66. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Shafique Virani sold 18,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $10.93, for a total transaction of $196,740.00. Following the completion of the transaction, the insider now owns 136,748 shares in the company, valued at $1,494,655.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 353,107 shares of company stock worth $3,856,834. Insiders own 19.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. KeyCorp increased their price target on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th. TD Cowen assumed coverage on shares of Recursion Pharmaceuticals in a report on Friday, January 26th. They set a “market perform” rating on the stock. Finally, Needham & Company LLC raised their target price on shares of Recursion Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $12.75.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.